Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence
(2019) In Acta Oncologica 58(8). p.1079-1086- Abstract
Background: Lung cancer patients have a risk of recurrence even after curatively intended surgery. Cell-free circulating tumor DNA (ctDNA) and circulating tumor marker measurements are easily accessible through peripheral blood and could potentially identify patients with worse prognosis. The aim of this study was to examine ctDNA in pre-operative plasma and the role of tumor markers in pre-operative serum for their predictive potential on risk of tumor recurrence. Methods: Mutation analysis by 26-gene targeted sequencing was performed on 157 lung adenocarcinomas (ACs) from patients surgically treated at the Lund University Hospital 2005–2014. Of these, 58 tumors from patients in stages I–IIIA (34 stage I, 14 stage II and 10 stage III)... (More)
Background: Lung cancer patients have a risk of recurrence even after curatively intended surgery. Cell-free circulating tumor DNA (ctDNA) and circulating tumor marker measurements are easily accessible through peripheral blood and could potentially identify patients with worse prognosis. The aim of this study was to examine ctDNA in pre-operative plasma and the role of tumor markers in pre-operative serum for their predictive potential on risk of tumor recurrence. Methods: Mutation analysis by 26-gene targeted sequencing was performed on 157 lung adenocarcinomas (ACs) from patients surgically treated at the Lund University Hospital 2005–2014. Of these, 58 tumors from patients in stages I–IIIA (34 stage I, 14 stage II and 10 stage III) with mutation(s) in EGFR, BRAF or KRAS were included. ctDNA from corresponding plasma (median 1.5 ml, range 1–1.6) was analyzed for one tumor-specific mutation in either of these three oncogenes using ultrasensitive IBSAFE droplet digital PCR (ddPCR). The tumor markers cancer antigen 125 (CA 125) and carbohydrate antigen 19-9 (CA 19-9) were analyzed in corresponding serum with electrochemiluminiscence immunoassay. Results: 6/7 patients with ctDNA and 19/51 without detected ctDNA were diagnosed with recurrence (log-rank test p =.001). 8/10 patients with positive serum tumor markers and 17/47 without tumor markers were diagnosed with recurrence (log-rank test, p =.0002). Fifteen patients had positive ctDNA and/or tumor markers, 12 of these had recurrence (log-rank test, p <.0001). Conclusion: A combination of tumor markers and ctDNA single mutation detection in low-volume pre-operative blood samples is a promising prognostic test. Prediction of recurrent disease in surgically treated early stage lung cancer can likely be further improved by using larger volumes of blood.
(Less)
- author
- Isaksson, Sofi LU ; George, Anthony M. LU ; Jönsson, Mats LU ; Cirenajwis, Helena LU ; Jönsson, Per ; Bendahl, Pär Ola LU ; Brunnström, Hans LU ; Staaf, Johan LU ; Saal, Lao H. LU and Planck, Maria LU
- organization
-
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Research Group Lung Cancer (research group)
- Breastcancer-genetics
- Translational Oncogenomics (research group)
- Melanoma Genomics (research group)
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- Personalized Breast Cancer Treatment (research group)
- Improved diagnostics and prognostics of lung cancer and metastases to the lungs (research group)
- Tumor microenvironment
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Oncologica
- volume
- 58
- issue
- 8
- pages
- 9 pages
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:85068118719
- pmid:31230502
- ISSN
- 0284-186X
- DOI
- 10.1080/0284186X.2019.1610573
- project
- Translational development and clinical applications of circulating tumor DNA for patient stratification, therapy guidance, and disease monitoring
- language
- English
- LU publication?
- yes
- id
- 779d51ae-e8cc-44b8-89ef-38d0e1917071
- date added to LUP
- 2019-07-10 14:46:37
- date last changed
- 2024-08-21 03:56:14
@article{779d51ae-e8cc-44b8-89ef-38d0e1917071, abstract = {{<p>Background: Lung cancer patients have a risk of recurrence even after curatively intended surgery. Cell-free circulating tumor DNA (ctDNA) and circulating tumor marker measurements are easily accessible through peripheral blood and could potentially identify patients with worse prognosis. The aim of this study was to examine ctDNA in pre-operative plasma and the role of tumor markers in pre-operative serum for their predictive potential on risk of tumor recurrence. Methods: Mutation analysis by 26-gene targeted sequencing was performed on 157 lung adenocarcinomas (ACs) from patients surgically treated at the Lund University Hospital 2005–2014. Of these, 58 tumors from patients in stages I–IIIA (34 stage I, 14 stage II and 10 stage III) with mutation(s) in EGFR, BRAF or KRAS were included. ctDNA from corresponding plasma (median 1.5 ml, range 1–1.6) was analyzed for one tumor-specific mutation in either of these three oncogenes using ultrasensitive IBSAFE droplet digital PCR (ddPCR). The tumor markers cancer antigen 125 (CA 125) and carbohydrate antigen 19-9 (CA 19-9) were analyzed in corresponding serum with electrochemiluminiscence immunoassay. Results: 6/7 patients with ctDNA and 19/51 without detected ctDNA were diagnosed with recurrence (log-rank test p =.001). 8/10 patients with positive serum tumor markers and 17/47 without tumor markers were diagnosed with recurrence (log-rank test, p =.0002). Fifteen patients had positive ctDNA and/or tumor markers, 12 of these had recurrence (log-rank test, p <.0001). Conclusion: A combination of tumor markers and ctDNA single mutation detection in low-volume pre-operative blood samples is a promising prognostic test. Prediction of recurrent disease in surgically treated early stage lung cancer can likely be further improved by using larger volumes of blood.</p>}}, author = {{Isaksson, Sofi and George, Anthony M. and Jönsson, Mats and Cirenajwis, Helena and Jönsson, Per and Bendahl, Pär Ola and Brunnström, Hans and Staaf, Johan and Saal, Lao H. and Planck, Maria}}, issn = {{0284-186X}}, language = {{eng}}, number = {{8}}, pages = {{1079--1086}}, publisher = {{Taylor & Francis}}, series = {{Acta Oncologica}}, title = {{Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence}}, url = {{http://dx.doi.org/10.1080/0284186X.2019.1610573}}, doi = {{10.1080/0284186X.2019.1610573}}, volume = {{58}}, year = {{2019}}, }